Rubicon Organics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Rubicon Organics wird ein Gewinn- und Umsatzwachstum von 76.1% bzw. 10.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 74.5% pro Jahr wachsen soll.

Wichtige Informationen

76.1%

Wachstumsrate der Gewinne

74.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	74.9%
Wachstumsrate der Einnahmen	10.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	17 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Benign Growth For Rubicon Organics Inc. (CVE:ROMJ) Underpins Stock's 26% Plummet

Jun 13

Is Rubicon Organics (CVE:ROMJ) Using Too Much Debt?

Jun 06

Would Rubicon Organics (CVE:ROMJ) Be Better Off With Less Debt?

Jan 09

Here's Why Rubicon Organics (CVE:ROMJ) Can Afford Some Debt

Sep 19

What Type Of Shareholders Own The Most Number of Rubicon Organics Inc. (CSE:ROMJ) Shares?

Jul 29

Gewinn- und Umsatzwachstumsprognosen

TSXV:ROMJ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	48	0	N/A	6	1
12/31/2024	43	-3	N/A	3	1
3/31/2024	40	-3	1	4	N/A
12/31/2023	40	-2	2	5	N/A
9/30/2023	41	-5	3	7	N/A
6/30/2023	42	-2	3	7	N/A
3/31/2023	39	-3	0	4	N/A
12/31/2022	36	-4	-2	2	N/A
9/30/2022	31	-2	-4	0	N/A
6/30/2022	28	-8	-7	-3	N/A
3/31/2022	24	-12	-10	-6	N/A
12/31/2021	23	-15	-16	-10	N/A
9/30/2021	21	-18	-20	-14	N/A
6/30/2021	17	-18	-22	-17	N/A
3/31/2021	13	-15	-23	-17	N/A
12/31/2020	9	-14	-20	-14	N/A
9/30/2020	5	-12	-21	-14	N/A
6/30/2020	1	-11	-22	-13	N/A
3/31/2020	0	-12	-21	-12	N/A
12/31/2019	N/A	-11	-18	-10	N/A
9/30/2019	-1	-9	-16	-11	N/A
6/30/2019	-1	-10	-19	-11	N/A
3/31/2019	0	-25	-16	-7	N/A
12/31/2018	N/A	-25	-18	-9	N/A
9/30/2018	2	-26	-19	-10	N/A
6/30/2018	1	-23	-11	-5	N/A
3/31/2018	1	-8	-13	-7	N/A
12/31/2017	1	-6	N/A	-4	N/A
12/31/2016	2	2	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ROMJ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ROMJ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ROMJ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ROMJDie Einnahmen des Unternehmens (10.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Canadian (7.3% pro Jahr).

Hohe Wachstumseinnahmen: ROMJDie Einnahmen des Unternehmens (10.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ROMJ in 3 Jahren voraussichtlich hoch sein wird

Rubicon Organics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 100%

Consensus EPS estimates have been downgraded.

Rubicon Organics Inc. Provides Earnings Guidance for the Year 2023

Rubicon Organics Inc. Provides Earnings Guidance for the Year 2023

Rubicon Organics Inc. Provides Earnings Guidance for the Full Year 2023

Consensus EPS estimates increase from loss to CA$0.00 profit, revenue downgraded

Recent updates

Rubicon Organics Inc. (CVE:ROMJ) Soars 27% But It's A Story Of Risk Vs Reward

Rubicon Organics Inc., Annual General Meeting, Jul 31, 2024

Consensus EPS estimates fall by 100%

First quarter 2024 earnings released: CA$0.033 loss per share (vs CA$0.01 loss in 1Q 2023)

Now 71% overvalued after recent price rise

Rubicon Organics Inc. Launches 1964 Supply Co. Full Spectrum Extracts (FSE) Vapes

Rubicon Organics Inc. to Report Q1, 2024 Results on May 15, 2024

Calculating The Fair Value Of Rubicon Organics Inc. (CVE:ROMJ)

Now 27% overvalued

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates have been downgraded.

New minor risk - Profitability

Rubicon Organics Inc. to Report Q4, 2023 Results on Mar 27, 2024

Is Rubicon Organics (CVE:ROMJ) A Risky Investment?

Rubicon Organics Inc. Appoints Janis Risbin as CFO

Third quarter 2023 earnings released: CA$0.029 loss per share (vs CA$0.036 profit in 3Q 2022)

Rubicon Organics Inc. Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Rubicon Organics Inc. to Report Q3, 2023 Results on Nov 14, 2023

Rubicon Organics™ Launches Wildflower™ Edibles Crafted with CBD, CBN & CBG

High number of new directors

Is Rubicon Organics (CVE:ROMJ) A Risky Investment?

Rubicon Organics Inc. Announces Board Appointments

Second quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.022 loss in 2Q 2022)

Rubicon Organics Inc. Provides Earnings Guidance for the Year 2023

Rubicon Organics Inc. Announces New Product Launches Under Simply Bare Organic and 1964 Supply Co

Rubicon Organics Inc. to Report Q2, 2023 Results on Aug 16, 2023

Rubicon Organics Inc., Annual General Meeting, Sep 14, 2023

Benign Growth For Rubicon Organics Inc. (CVE:ROMJ) Underpins Stock's 26% Plummet

Is Rubicon Organics (CVE:ROMJ) Using Too Much Debt?

First quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.027 loss in 1Q 2022)

Rubicon Organics Inc. Provides Earnings Guidance for the Full Year 2023

Rubicon Organics Inc. to Report Q1, 2023 Results on May 23, 2023

Independent Director recently bought CA$64k worth of stock

Consensus EPS estimates increase from loss to CA$0.00 profit, revenue downgraded

Less than half of directors are independent

Insider recently sold CA$57k worth of stock

Would Rubicon Organics (CVE:ROMJ) Be Better Off With Less Debt?

Rubicon Organics Inc. Launches Eleven New Products in Quebec Under the Simply Bare™ Organic and 1964 Supply Co.™ Brands

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Insufficient new directors

Rubicon Organics Inc. Announces Resignation of Julie Lassonde as Board Member

Rubicon Organics Inc. to Report Q3, 2022 Results on Nov 14, 2022

Rubicon Organics Inc. Reiterates Earnings Guidance for the Year 2022

Here's Why Rubicon Organics (CVE:ROMJ) Can Afford Some Debt

Price target decreased to CA$2.75

Rubicon Organics Inc. Announces Resignation of Jesse McConnell as Chief Executive Officer, Effective December 31, 2022

Rubicon Organics Inc. Announces Resignation of Bryan Disher from the Board of Directors

Rubicon Organics Inc. to Report Q2, 2022 Results on Aug 15, 2022

Rubicon Organics Inc., Annual General Meeting, Sep 27, 2022

Rubicon Organics Inc. Announces Board Changes

Rubicon Organics Inc. to Report Q1, 2022 Results on May 24, 2022

Rubicon Organics Inc. Announces the Departure of Tim Roberts, Formerly President

Rubicon Organics Inc. to Report Q4, 2021 Results on Apr 18, 2022

Rubicon Organics Inc. to Report Q4, 2021 Results on Apr 14, 2022

Rubicon Organics Inc. Announces Launches Five New Strains

Rubicon Organics Launches New SKUs

Rubicon Organics Inc. Secures R&D License from Health Canada

Rubicon Organics Inc. Provides Revenues Guidance for the Year 2021

Rubicon Organics Inc. to Report Q4, 2020 Results on Apr 06, 2021

Rubicon Organics Enters into Extraction Services Agreement with The Valens Company

Rubicon Organics Inc. has completed a Composite Units Offering in the amount of CAD 20 million.

National Cannabis Distribution Enters into Exclusive Wholesale Distribution Agreement with Rubicon Organics in Saskatchewan

Rubicon Organics Inc. Receives Sales Amendment from Health Canada

Rubicon Organics Inc. Receives First Purchase Order from Quebec

Julie Lassonde to Join Rubicon Organics Board of Directors

Rubicon Organics Inc. Launches LAB THEORY™ Concentrate Brand

Rubicon Organics Inc. Executes Letter of Understanding with Société québécoise du cannabis